Hepatoblastoma is a type of cancer that starts in the liver of young children. It's a rare cancer, and doctors usually find it during a routine ultrasound.
Every report comes from a Lived member, sent anonymously.
Have you tried Cisplatin for Hepatoblastoma?
Hepatoblastoma is a cancer that starts in the liver of young children. It is the most common type of childhood liver cancer, although it is still rare, and it usually appears before age 3. The tumor grows from cells that resemble the immature liver cells of a developing baby, which is why it is almost entirely a disease of early childhood rather than of adults. Many children have no obvious symptoms until the tumor is fairly large. Parents or a doctor may notice a firm lump or a swollen belly, sometimes with pain, poor appetite, weight loss, nausea or vomiting. Occasionally the tumor releases a hormone that causes early signs of puberty in boys. Hepatoblastoma is different from the liver cancer adults usually get (hepatocellular carcinoma), which is linked to hepatitis, cirrhosis and heavy alcohol use and is treated differently.
In most children, hepatoblastoma appears without any identifiable cause. It is not caused by anything parents did or did not do, and it is not linked to the hepatitis or alcohol exposure behind adult liver cancer. A few conditions raise the risk considerably. They include being born very prematurely with a very low birth weight, Beckwith-Wiedemann syndrome and hemihyperplasia (overgrowth conditions in which the body or one side of it grows faster than usual), Simpson-Golabi-Behmel syndrome, trisomy 18, Aicardi syndrome, some glycogen storage diseases, and familial adenomatous polyposis (FAP), an inherited condition that runs in families. Even with a risk factor, most children never develop the cancer. Because the risk is high enough in Beckwith-Wiedemann syndrome, hemihyperplasia, Simpson-Golabi-Behmel syndrome and trisomy 18, these children are usually screened with an abdominal ultrasound and a blood test for alpha-fetoprotein (AFP), a protein these tumors release, every 3 months from birth (or from diagnosis of the syndrome) until age 4. This catches most tumors early, when they are smaller and easier to remove. Routine screening for children in families with FAP is debated, because the cancer develops in fewer than 1 in 100 of them.
Diagnosis usually begins with a physical exam and an ultrasound of the abdomen, followed by an MRI or CT scan to show the tumor's size, its relationship to the liver's major blood vessels, and whether it has spread, most often to the lungs. A key blood test measures AFP, which the tumor usually releases in large amounts. A high AFP supports the diagnosis and later becomes a useful way to track whether treatment is working, since the level should fall as the tumor shrinks. It is not proof on its own: newborns normally have very high AFP that falls to the usual adult range by about age 1, and benign tumors, hepatitis and other conditions can also raise it. Blood counts and liver tests check the child's overall health before treatment. A biopsy, a small sample of the tumor examined under a microscope, usually confirms the diagnosis and identifies the tumor's type. Some types, such as pure fetal tumors, behave more gently, while small cell undifferentiated tumors are more aggressive and need stronger treatment. When a small tumor can be removed straight away, the surgery itself may provide the tissue. Instead of a traditional stage, doctors use a grouping system called PRETEXT. It divides the liver into four sections and records how many hold tumor (groups I to IV), along with features such as spread into large veins, multiple tumors, rupture or spread to the lungs. The group largely determines whether surgery is possible right away.
The goal of treatment is cure, and the cornerstone is removing the entire tumor. Care is led by a pediatric oncologist (a children's cancer specialist) working with a pediatric surgeon experienced in liver surgery, ideally at a center with a liver transplant program. Only about 20% to 30% of children have a tumor small enough to remove at diagnosis. They have surgery to take out the affected part of the liver (a partial hepatectomy). Most then receive chemotherapy to lower the chance of the cancer returning. Children whose small tumor is entirely the favorable pure fetal type may need no further treatment, only close follow-up. For the other 70% to 80%, chemotherapy comes first to shrink the tumor, followed by a reassessment of whether surgery can remove it. When the tumor still involves too much of the liver or its main blood vessels but has not spread beyond the liver, a liver transplant can offer a cure, with long-term survival of about 70% to 80% after transplant. Children whose cancer has spread to the lungs receive chemotherapy aimed at both sites, and remaining lung nodules may be removed surgically. Cisplatin, a platinum chemotherapy drug, is the backbone of treatment, often combined with other drugs for higher-risk tumors. Its most important long-term trade-off is permanent hearing loss. Sodium thiosulfate (Pedmark), given 6 hours after each cisplatin dose, is approved to reduce this risk in children whose tumor has not spread; in a trial of children with hepatoblastoma it roughly halved the rate of hearing loss without reducing survival. Hearing tests are part of routine monitoring. Other options are used in specific situations: delivering chemotherapy or radiation-carrying beads directly into the artery that feeds the liver (chemoembolization or radioembolization), radiation therapy, and heat-based ablation for some recurrences. Clinical trials are common in childhood cancer and may be offered.
Treatment typically spans several months, with cycles of chemotherapy given in the hospital, surgery partway through, and frequent blood tests and scans. Chemotherapy lowers blood counts, so children are more prone to infection, and many families adjust daily routines, child care and work around hospital visits. Child life specialists, social workers and nutrition support are usually part of the team. The outlook depends heavily on how much of the liver is involved, whether the cancer has spread, the tumor's type, and how well it responds to chemotherapy. Overall, about 70% of children are alive 5 years after diagnosis, and outcomes are considerably better when the tumor is confined to one or two sections of the liver and can be removed completely. Spread to the lungs or involvement of the whole liver makes treatment harder, though many of these children are still cured. After treatment ends, AFP blood tests and imaging continue for some time, because they can show whether the cancer has come back, either in the liver or elsewhere in the body. Survivors also need long-term follow-up for late effects, which can include hearing loss, problems with liver function, changes in mood, learning or memory, and a second cancer later in life. A survivorship clinic can coordinate these checks as the child grows.
Have a child seen by their doctor if you notice a lump or swelling in the belly, ongoing abdominal pain, poor appetite, unexplained weight loss or repeated vomiting. For children with a syndrome that raises the risk, keep to the screening schedule even when they seem well. During chemotherapy, call the cancer team right away, day or night, for a fever of 100.5 F (38 C) or higher, chills, or redness, swelling or drainage around a central line. Infections during treatment can become serious quickly. Ask the team before giving fever-reducing medicine, since it can hide a fever that needs attention. After treatment, tell the care team about any new hearing difficulty, a new lump or swelling, or a rising AFP result between scheduled visits.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Hepatoblastoma is like, what's helped you, or ask the community a question.